CCG-1423 50mg | Purity Not Available
Selleck Chemicals
CCG-1423 is a specific RhoA pathway inhibitor, which inhibits SRF-mediated transcription.
More Information Supplier PageCCG-1423 is a specific RhoA pathway inhibitor, which inhibits SRF-mediated transcription.
More Information Supplier PageBMH-21 is a DNA intercalator, which binds ribosomal DNA and inhibits RNA polymerase I (Pol I) transcription.
More Information Supplier PageYK-4-279 is a potent inhibitor of EWS-FLI1 binding to RNA helicase A (RHA).
More Information Supplier PageYK-4-279 is a potent inhibitor of EWS-FLI1 binding to RNA helicase A (RHA).
More Information Supplier PageSP2509 (HCI-2509) is a selective histone demethylase LSD1 inhibitor with IC50 of 13 nM, showing no activity against MAO-A, MAO-B, lactate dehydrogenase and glucose oxidase. SP2509 induces apoptosis and promotes autophagy.
More Information Supplier PageSP2509 (HCI-2509) is a selective histone demethylase LSD1 inhibitor with IC50 of 13 nM, showing no activity against MAO-A, MAO-B, lactate dehydrogenase and glucose oxidase. SP2509 induces apoptosis and promotes autophagy.
More Information Supplier PageOF-1 is a potent inhibitor of BRPF1B and BRPF2 bromodomain with Kd of 100 nM and 500 nM, respectively.
More Information Supplier PageSalirasib (Farnesylthiosalicylic acid, FTS) is a potent competitive prenylated protein methyltransferase (PPMTase) inhibitor with Ki of 2.6 μM, which inhibits Ras methylation. Salirasib exerts antitumor effects and induces autophagy. Phase 2.
More Information Supplier PageSalirasib (Farnesylthiosalicylic acid, FTS) is a potent competitive prenylated protein methyltransferase (PPMTase) inhibitor with Ki of 2.6 μM, which inhibits Ras methylation. Salirasib exerts antitumor effects and induces autophagy. Phase 2.
More Information Supplier PageSecinH3 is a selective cytohesin inhibitor with IC50 of 2.4 μM, 5.4 μM, 5.4 μM, 5.6 μM, 5.6 μM, and 65 μM for hCyh2, hCyh1, mCyh3, hCyh3, drosophila steppke, and yGea2-S7, respectively.
More Information Supplier Page